Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Susan M O'Brien"'
Autor:
Mazyar Shadman, Alessandra Tedeschi, Leyla Mohseninejad, Keri Yang, Nicole Lamanna, Sheng Xu, Aileen Cohen, Swetha Challagulla, Mei Xue, Rhys Williams, Susan M. O’Brien, Jennifer R. Brown, Constantine Tam
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/e548c73b0c6d4a53b356797818e0367a
Autor:
John N. Allan, Javier Pinilla-Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan M. O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte A. Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 107, Iss 4 (2021)
Externí odkaz:
https://doaj.org/article/2b83f0254400461d8896d202887eadb7
Autor:
Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lym
Externí odkaz:
https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55
Autor:
Farhad Ravandi, Megan Othus, Susan M. O'Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y.C. Wong, Martin S. Tallman, Elisabeth Paietta, Janis Racevskis, Geoffrey L. Uy, Mary Horowitz, Naoko Takebe, Richard Little, Uma Borate, Partow Kebriaei, Laura Kingsbury, Hagop M. Kantarjian, Jerald P. Radich, Harry P. Erba, Frederick R. Appelbaum
Publikováno v:
Blood Advances, Vol 1, Iss 3, Pp 250-259 (2016)
Abstract: This multicenter trial was conducted to determine whether the addition of dasatinib to chemotherapy followed by an allogeneic hematopoietic cell transplant (HCT) in patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic le
Externí odkaz:
https://doaj.org/article/a180372f755a43b6b6c75bb36fa3a69e
Autor:
Anjali S. Advani, A. Douglas Laird, Alexander Neuhof, Erik Vandendries, Barbara Sleight, Kevin Nguyen, M. Luisa Paccagnella, Tao Wang, Matthias Stelljes, Susan M. O'Brien, Elias Jabbour, Daniel J. DeAngelo, Ryan D. Cassaday, Wendy Stock, Hagop M. Kantarjian
Purpose:We assessed the relationship between cluster of differentiation-22 (CD22) expression and outcomes of inotuzumab ozogamicin versus standard of care (SC) in INO-VATE (NCT01564784).Patients and Methods:Adults with relapsed/refractory B-cell prec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf030dd6288dcdbb24ed88988e18f897
https://doi.org/10.1158/1078-0432.c.6530325
https://doi.org/10.1158/1078-0432.c.6530325
Autor:
Anjali S. Advani, A. Douglas Laird, Alexander Neuhof, Erik Vandendries, Barbara Sleight, Kevin Nguyen, M. Luisa Paccagnella, Tao Wang, Matthias Stelljes, Susan M. O'Brien, Elias Jabbour, Daniel J. DeAngelo, Ryan D. Cassaday, Wendy Stock, Hagop M. Kantarjian
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4552990af2a17d599a895f6e51106001
https://doi.org/10.1158/1078-0432.22479924
https://doi.org/10.1158/1078-0432.22479924
Autor:
Rajat Bannerji, Jon E Arnason, Ranjana H Advani, Jennifer R Brown, John N Allan, Stephen M Ansell, Jeffrey A Barnes, Susan M O'Brien, Julio C Chávez, Johannes Duell, Andreas Rosenwald, Jennifer L Crombie, Melanie Ufkin, Jingjin Li, Min Zhu, Srikanth R Ambati, Aafia Chaudhry, Israel Lowy, Max S Topp
Publikováno v:
The Lancet Haematology. 9:e327-e339
Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells. We aimed to evaluate the safety and antitumour activity of odronextamab in patients with relapsed or refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c7cea0a7b2e4936015a8f286ba40f6
https://doi.org/10.1016/s2352-3026(22)00072-2
https://doi.org/10.1016/s2352-3026(22)00072-2
Autor:
Paul M. Barr, Stephen D. Smith, Mark J. Roschewski, Susan M. O’Brien, Jeff P. Sharman, Jason M. Melear, Priti Patel, Roser Calvo, Helen Yang, Stephen E. Spurgeon
Publikováno v:
Leukemia & Lymphoma. 63:1728-1732
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d9d02a6c9576008a6161e84609eb381
https://doi.org/10.1080/10428194.2022.2043301
https://doi.org/10.1080/10428194.2022.2043301
Autor:
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 41, iss 5
PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cebead271e6234bf0b9f19719ee31aa4
https://ruj.uj.edu.pl/xmlui/handle/item/305371
https://ruj.uj.edu.pl/xmlui/handle/item/305371
Publikováno v:
Cancers, vol 15, iss 6
Cellular therapies can be viewed as both the newest and oldest techniques for treating chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT). On one hand, allogeneic hematopoietic stem cell transplantation (alloHSCT) has been availab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a397cc575374dd404cfb64a301a8e5d1